TOKYO -- Fujifilm Holdings' regenerative medicine subsidiary appears on track to report its first-ever operating profit in the fiscal year ending in March.
Japan Tissue Engineering likely will generate an 11 million yen ($108,000) profit, compared with an operating loss of 700 million yen a year earlier. The company, the first in Japan to receive government approval for a regenerative medicine product, now sells cultured skin for burn victims, among other things. Because the number of medical facilities that can handle skin transplants continues to increase, the company's sales are expected to jump 50% and cushion the impact of R&D expenditures.
